Logo image of CMMB

CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Fundamental Analysis

NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD

1.34  +0.03 (+2.29%)

After market: 1.39 +0.05 (+3.73%)

Fundamental Rating

2

CMMB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. CMMB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CMMB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CMMB had negative earnings in the past year.
In the past 5 years CMMB always reported negative net income.
CMMB had a negative operating cash flow in each of the past 5 years.
CMMB Yearly Net Income VS EBIT VS OCF VS FCFCMMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -68.90%, CMMB is not doing good in the industry: 64.66% of the companies in the same industry are doing better.
With a Return On Equity value of -88.24%, CMMB perfoms like the industry average, outperforming 49.29% of the companies in the same industry.
Industry RankSector Rank
ROA -68.9%
ROE -88.24%
ROIC N/A
ROA(3y)-64.32%
ROA(5y)N/A
ROE(3y)-79.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMMB Yearly ROA, ROE, ROICCMMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

CMMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMMB Yearly Profit, Operating, Gross MarginsCMMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

CMMB has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CMMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CMMB Yearly Shares OutstandingCMMB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M
CMMB Yearly Total Debt VS Total AssetsCMMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

There is no outstanding debt for CMMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
CMMB Yearly LT Debt VS Equity VS FCFCMMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 4.57 indicates that CMMB has no problem at all paying its short term obligations.
CMMB has a Current ratio (4.57) which is comparable to the rest of the industry.
A Quick Ratio of 4.57 indicates that CMMB has no problem at all paying its short term obligations.
CMMB has a Quick ratio (4.57) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.57
Quick Ratio 4.57
CMMB Yearly Current Assets VS Current LiabilitesCMMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CMMB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.66% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.71%
EPS Next 2Y14.25%
EPS Next 3Y8.52%
EPS Next 5Y14.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMMB Yearly Revenue VS EstimatesCMMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M 500M
CMMB Yearly EPS VS EstimatesCMMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CMMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMMB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMMB Price Earnings VS Forward Price EarningsCMMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMMB Per share dataCMMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.25%
EPS Next 3Y8.52%

More info and screens

0

5. Dividend

5.1 Amount

CMMB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHEMOMAB THERAPEUTICS LTD

NASDAQ:CMMB (4/28/2025, 8:00:40 PM)

After market: 1.39 +0.05 (+3.73%)

1.34

+0.03 (+2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners16.69%
Inst Owner Change0.19%
Ins Owners10.03%
Ins Owner Change0%
Market Cap25.27M
Analysts84.44
Price Target9.18 (585.07%)
Short Float %19.08%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-892.06%
Min EPS beat(2)-1720.73%
Max EPS beat(2)-63.4%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.55
P/tB 1.55
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpSN/A
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.9%
ROE -88.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.32%
ROA(5y)N/A
ROE(3y)-79.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.57
Quick Ratio 4.57
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)307.05%
Cap/Depr(5y)231.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y28.71%
EPS Next 2Y14.25%
EPS Next 3Y8.52%
EPS Next 5Y14.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y49.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.91%
OCF growth 3YN/A
OCF growth 5YN/A